Roberts Glore & Co. Inc. IL Takes $4.32 Million Position in Stryker Corporation $SYK

Key Points

• Roberts Glore & Co. Inc. IL acquired 13,705 Stryker shares worth approximately $4.32 million in the second quarter, making the stock its 19th-largest holding. Institutional investors and hedge funds collectively own 77.09% of Stryker.
• Stryker reported quarterly EPS of $3.69, beating estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company maintained 2026 EPS guidance of $14.95–$15.10.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $386.28, while Stryker declared a quarterly dividend of $0.88 per share, equivalent to a 1.1% annual yield.

Roberts Glore & Co. Inc. IL bought a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 13,705 shares of the medical technology company's stock, valued at approximately $4,315,000. Stryker accounts for approximately 1.1% of Roberts Glore & Co. Inc. IL's portfolio, making the stock its 19th biggest holding.

A number of other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new stake in shares of Stryker during the 4th quarter worth about $1,822,272,000. Auto Owners Insurance Co grew its stake in Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Legal & General Group Plc acquired a new position in Stryker in the 2nd quarter valued at about $707,212,000. Jupiter Topco LLC bought a new position in Stryker in the 2nd quarter valued at about $681,581,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker during the second quarter worth approximately $464,506,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company's stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 355,370 shares of company stock worth $119,447,201 in the last ninety days. Company insiders own 4.60% of the company's stock.

Stryker Trading Up 1.0%

Shares of SYK stock opened at $331.06 on Wednesday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The stock's fifty day simple moving average is $327.80 and its 200 day simple moving average is $331.95. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $126.98 billion, a P/E ratio of 34.31, a P/E/G ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 earnings per share. The business's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price target for the company. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating for the company in a research note on Monday, May 4th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Finally, Piper Sandler cut their price target on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source